Commentary on Larance et al . (2020): Priorities and concerns of people who use opioids are key to scaling up XR‐buprenorphine-Reference-Cited by-同舟云学术

Commentary on Larance et al . (2020): Priorities and concerns of people who use opioids are key to scaling up XR‐buprenorphine

Published:2020-04-18 Issue:7 Volume:115 Page:1306-1307
ISSN:0965-2140
Container-title:Addiction
language:en
Short-container-title:Addiction

Author:

Shover Chelsea L.¹^ORCID

Affiliation:

1. Department of Psychiatry and Behavioral SciencesStanford University School of Medicine 1070 Arastradero Rd. Ste 200 Palo Alto CA USA

Funder

National Institute on Drug Abuse

Publisher

Wiley

Subject

Psychiatry and Mental health,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/add.15048

Reference5 articles.

1. Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia

2. Predictors of availability of long-acting medication for opioid use disorder

3. Medicaid.gov.State drug utilization data2019. Available from:https://data.medicaid.gov/browse?category=State+Drug+Utilization&limitTo=datasets&sortBy=newest.

4. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population

5. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018–2022;Addiction;2024-08-16

2. Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients;Addiction;2024-08-05

3. Comparative effectiveness of extended release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients;2024-01-24

4. Availability and prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018-2022;2024-01-07

5. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort;Drug and Alcohol Dependence;2021-08